Saffron Walden, 26th January 2022 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services to life science organisations globally, is delighted that Professors Daniel Longley, Tim Harrison and colleagues at Queen’s University Belfast have entered into a collaboration and licensing agreement with Ipsen. The agreement provides an exclusive licence to research, develop, manufacture and commercialise FLIP inhibitors. Domainex has supported the FLIP inhibitor programme from its inception.
News
Life science specialists, AMSBIO, have made a new strategic investment to enhance the level of support to its sizeable and growing base of customers across the European Union.
On December 30th, 2021, AMSBIO opened a new office in Alkmaar, Netherlands. The new AMSBIO Europe BV office is already providing EU customers rapid, easy access to the company’s extensive range of top-quality products and consumables.
The Babraham Research Campus – one of the UK’s leading locations supporting early-stage bioscience enterprise – has been given the go ahead to expand, to ensure the UK life science research and development sector can continue to deliver world-changing health solutions.
Through the construction of a sustainable, multi tenanted office and laboratory building, the new development will provide space for new life sciences companies, and for existing companies to grow, enabling the UK to continue to compete in the global life sciences sector.
Click here to view the January 2022 edition of Dates for Your Diary
SAN FRANCISCO, Jan. 19, 2022 /PRNewswire/ -- Altos Labs™ (Altos™) launched today as a new biotechnology company dedicated to unraveling the deep biology of cellular rejuvenation programming. Altos' mission is to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life. The company launches with a community of leading scientists, clinicians, and leaders from both academia and industry working together towards this common mission.
WILMINGTON, Mass. & BOSTON--(BUSINESS WIRE)--Jan. 19, 2022-- Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, LLC (“Valo”), the technology company using human-centric data and computation powered by artificial intelligence (AI) to transform the drug discovery and development process, today announced the formation of a multiyear strategic partnership.
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR COMMENCES US PHASE I CLINICAL TRIAL OF AT247 ULTRA-RAPID INSULIN IN COMBINATION WITH AN INSULIN PUMP
First patient dosed in potential game-changing diabetes combination therapy
At a glance:
We would like to invite you to participate in the SLAS Mentor Match program. SLAS is committed to transforming life sciences through research. We are an international professional society of academic, industry and government researchers as well as developers and providers of laboratory automation tools. The SLAS mentor program was developed to encourage experienced professionals (mentors) in our diverse community to pass on their knowledge and experience to young professionals (mentees).